menu
    • menu
    [{"orgOrder":0,"company":"NHS Greater Glasgow and Clyde","sponsor":"University of Glasgow | NuvOx Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dodecafluoropentane","moa":"Blood gas interface","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS Greater Glasgow and Clyde","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NHS Greater Glasgow and Clyde \/ University of Glasgow | NuvOx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NHS Greater Glasgow and Clyde \/ University of Glasgow | NuvOx Pharma"},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"University of Arkansas | Stanford University | Washington Regional Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dodecafluoropentane","moa":"Blood gas interface","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"NuvOx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"NuvOx Pharma \/ University of Arkansas | Stanford University | Washington Regional Medical Center","highestDevelopmentStatusID":"9","companyTruncated":"NuvOx Pharma \/ University of Arkansas | Stanford University | Washington Regional Medical Center"},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dodecafluoropentane","moa":"Blood gas interface","graph1":"Oncology","graph2":"Phase II","graph3":"NuvOx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuvOx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuvOx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dodecafluoropentane","moa":"Blood gas interface","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NuvOx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuvOx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NuvOx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"FYR Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Dodecafluoropentane","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"FYR Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FYR Bio \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"FYR Bio \/ National Cancer Institute"}]

    Find Clinical Drug Pipeline Developments & Deals for Dodecafluoropentane

    Menu

    Dodecafluoropentane

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            FYR Bio

                            Country arrow
                            AES
                            Not Confirmed

                            FYR Bio

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Fyr Bio, NuvOx Get NCI Grant for Glioblastoma Liquid Biopsy Trial

                            Details : The funding will support the development of Dodecafluoropentane for glioblastoma (GBM) treatment.

                            Product Name : NanO2TM

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 19, 2025

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NHS Greater Glasgow and Clyde

                            Country arrow
                            AES
                            Not Confirmed

                            NHS Greater Glasgow and Clyde

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : University of Glasgow | NuvOx Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NanO2 in Large VessEL Occlusion Stroke (NOVEL)

                            Details : Dodecafluoropentane is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : University of Glasgow | NuvOx Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NuvOx Pharma

                            U.S.A arrow
                            AES
                            Not Confirmed

                            NuvOx Pharma

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

                            Details : Dodecafluoropentane is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Distress Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2024

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NuvOx Pharma

                            U.S.A arrow
                            AES
                            Not Confirmed

                            NuvOx Pharma

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : University of Arkansas | Stanford University | Washington Regional Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NanO2 for Large Vessel Occlusion Stroke

                            Details : Dodecafluoropentane is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2022

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : University of Arkansas | Stanford University | Washington Regional Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NuvOx Pharma

                            U.S.A arrow
                            AES
                            Not Confirmed

                            NuvOx Pharma

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of NanO2â„¢ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

                            Details : Dodecafluoropentane is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2019

                            Lead Product(s) : Dodecafluoropentane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth